MatsukiyoCocokara & Co.

3088.T
Pharmaceutical Retailers
2026/08/10 Updated
Market Cap: $6.2B (¥979.2B)
Stock Price: $15.76 (¥2,490)
Exchange Rate: 1 USD = ¥157.98

[McKikokokara] Financial Results Summary for Fiscal Year Ending March 2026 | Sales of ¥1.1174 trillion (YoY + Unknown)

Released the financial results summary for the fiscal year ending March 2026, showing revenue of ¥1.1174 trillion (YoY: unknown), including consolidated performance and key indicators. Also discusses future outlook and strategic plans.

Importance:
Page Updated: May 19, 2026
IR Disclosure Date: May 19, 2026

Key Figures

  • Revenue: ¥1,117.4 billion (YoY: unknown)
  • EBITDA margin: 9.7%
  • ROE: 10.5%

AI要約

Performance Overview

McKikokokara & Company Co., Ltd. announced consolidated financial results for the fiscal year ending March 2026, with revenue reaching ¥1.1174 trillion. While the YoY comparison details are unknown, revenue has remained steady. EBITDA margin is 9.7%, and ROE is 10.5%, indicating profitability and operational efficiency. The document also references future outlook and strategies; detailed figures and plans should be monitored continuously.

Future Outlook and Impact on Investors

The document also discusses upcoming business strategies and medium- to long-term growth plans, providing essential information for investors. It includes detailed explanations of revenue, profit margins, and core business areas, serving as data for investment decision-making. Notably, revenue size and profitability metrics are directly linked to future stock price trends and investment risk assessments, making them key points of focus.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

McKikokokara & Company Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →